capstantx.comHealthcare / Healthcare providers & servicesFounded: 2021Funding to Date: $340MM
Capstan Therapeutics is a biotechnology company that strives to develop new treatments for a variety of diseases using in vivo cell engineering, which is a method that aims to modify cells inside the body. Their core technology involves targeted lipid nanoparticles (tLNPs) seeking to manipulate cells for therapeutic purposes. Areas of interest for the company include oncology, fibrosis, inflammatory disease, and blood disorders. Capstan Therapeutics was founded in 2021 and is headquartered in San Diego, California.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/20/2024 | Series B | $175MM | $xx.xx | $525.33MM | RA Capital Management, Forbion, Johnson & Johnson, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly, Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
51,956,524
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
RA Capital Management, Forbion, Johnson & Johnson, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly, Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, Vida Ventures
|
||||||
09/14/2022 | Series A | $102MM | $xx.xx | $309.58MM | Pfizer Ventures, Leaps by Bayer, Eli Lilly and Company, Bristol Myers Squibb, Polaris Partners, Alexandria Venture Investments | |
Price per Share
$xx.xx
Shares Outstanding
30,283,226
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
Pfizer Ventures, Leaps by Bayer, Eli Lilly and Company, Bristol Myers Squibb, Polaris Partners, Alexandria Venture Investments
|
||||||
11/01/2021 | Series Seed | $63MM | $xx.xx | $105MM | Novartis Venture Fund, OrbiMed, RA Capital, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
37,446,500
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
Novartis Venture Fund, OrbiMed, RA Capital, Vida Ventures
|